SCHEDULE: Rubric Capital and David Rosen Disclose 7.12% Stake in Trevi Therapeutics

Rubric Capital Management LP and David Rosen have jointly disclosed a beneficial ownership of 7.12% of Trevi Therapeutics, Inc.'s common stock, totaling 8,531,860 shares.

Summary

• Rubric Capital Management LP and David Rosen, Managing Member of Rubric Capital Management GP LLC, have filed a Schedule 13G jointly.
• The filing reports beneficial ownership of 8,531,860 shares of Common Stock of Trevi Therapeutics, Inc.
• This ownership represents 7.12% of the total class of securities.
• The percentage is calculated based on 119,902,915 shares of Common Stock outstanding, as reported in Trevi Therapeutics' Prospectus filed on June 4, 2025, and a press release issued on June 5, 2025, after giving effect to the completion of an offering and the full exercise of underwriters' overallotment option.
• Rubric Capital Management LP is a Delaware limited partnership, and David Rosen is a U.S. citizen.
• Both reporting persons share voting and dispositive power over all 8,531,860 shares.
• Rubric Capital Master Fund LP, an investment fund advised by Rubric Capital, has the right to receive or direct dividends or proceeds from more than 5% of the Common Stock.

Sentiment

Score: 5

Explanation: This is a factual report of beneficial ownership, which inherently carries no positive or negative sentiment regarding company performance or outlook.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• Rubric Capital Management LP and David Rosen certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of Trevi Therapeutics, Inc., nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Rubric Capital Management and David Rosen may be viewed positively by other investors, signaling confidence in Trevi Therapeutics, Inc. and potentially influencing market perception and trading activity.

Key Dates

Keywords

Trevi Therapeutics, Rubric Capital Management, David Rosen, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Ownership, SEC Filing